{"links":{"html":"https://www.erudio.com/reports/rmc-gi-102-nct06445062","json":"https://www.erudio.com/reports/rmc-gi-102-nct06445062.json","markdown":"https://www.erudio.com/reports/rmc-gi-102-nct06445062.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"rmc-gi-102-06445062"}},"request":"https://www.erudio.com/contact?report=rmc-gi-102-06445062"},"offer":{"cited_commentary_sources":19,"verified_hcp_statements":38,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":12,"optional":true,"price_per_verified_person_usd":15,"price_usd":180,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"rmc-gi-102-nct06445062"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=rmc-gi-102-06445062","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/rmc-gi-102-nct06445062","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T03:40:57.571651Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the limitations. The trial's registration date is now stated."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":1},"aspects":[{"claim_count":4,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":4,"title":"Primary endpoint: Adverse events (Subprotocols A-F)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Dose limiting toxicities (Subprotocols A-F)"},{"claim_count":10,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":10,"title":"Primary endpoint: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)"},{"claim_count":5,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":8,"title":"The comparison"},{"claim_count":10,"coverage":"discussed","id":"T7","registry_field":"outcomesModule","source_count":8,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":3,"coverage":"discussed","id":"A1","source_count":2,"title":"Chemotherapy scheduling and dose delivery"},{"claim_count":3,"coverage":"discussed","id":"A2","source_count":3,"title":"Response prediction, patient selection and residual unmet need"},{"claim_count":11,"coverage":"discussed","id":"A3","source_count":9,"title":"Confirmatory trials and chemotherapy-sparing strategies"},{"claim_count":1,"coverage":"discussed","id":"A4","source_count":1,"title":"Geographic trial access and referral implications"},{"claim_count":5,"coverage":"discussed","id":"A5","source_count":3,"title":"Regulatory communication and authored reactions"}],"counts":{"cited_sources":19,"claims_by_expression_type":{"comparison":2,"experience":1,"interpretation":11,"opinion":11,"question":1,"restatement":10,"unspecified":2},"claims_by_kind":{"attributed_opinion":19,"source_observation":19},"clinician_statements":13,"evidence_units":36,"findings":7,"organisational_accounts":4,"people_cited":15,"people_identity_verified":12,"people_total":16,"screened_sources":31,"verified_claims":38},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":4,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":2,"passages":4,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"No added toxicity is not the same as a low treatment burden"},{"id":"F2","structure":{"claims":4,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":3},"has_counterview":false,"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":4,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"Daraxonrasib enthusiasm is an early-signal interpretation, not demonstrated survival superiority"},{"id":"F3","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":5},"has_counterview":false,"limitations":3,"links":{"context":1,"support":8},"ma_question":true,"named_voices":5,"passages":7,"sources":7,"sources_by_kind":{"commentary":6,"media":1}},"title":"Zoldonrasib response enthusiasm carries explicit design and follow-up qualifications"},{"id":"F4","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Response prediction and patient selection remain explicit information needs"},{"id":"F5","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":3},"has_counterview":false,"limitations":3,"links":{"context":1,"support":6},"ma_question":true,"named_voices":2,"passages":7,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Adding an inhibitor, using monotherapy and pursuing a chemotherapy-free doublet are different strategies"},{"id":"F6","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":1},"has_counterview":false,"limitations":3,"links":{"context":0,"support":2},"ma_question":true,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"media":1}},"title":"A conditional practice-change expectation is accompanied by a local access limitation"},{"id":"F7","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Regulatory amplification is not multiple independent clinical endorsements or first-line approval"}],"medical_affairs_question":"Are response-prediction biomarkers being analyzed, which patient-selection criteria clarify who benefits, and what comparative benefit–toxicity evidence would justify changing first-line care?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Incremental toxicity and total treatment burden answer different questions"},{"id":"section-2","level":2,"title":"Daraxonrasib: enthusiasm for progress, with comparative claims kept tentative"},{"id":"section-3","level":2,"title":"Zoldonrasib: strong response language does not settle synergy, survival or backbone choice"},{"id":"section-4","level":2,"title":"Predictive biomarkers and selection are questions, not established omissions"},{"id":"section-5","level":2,"title":"Competing strategies must remain separate"},{"id":"section-6","level":2,"title":"Trial access limits the immediate meaning of future practice change"},{"id":"section-7","level":2,"title":"Regulatory news and authored reactions have different evidentiary roles"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase1, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2}],"id":"T1","label":"Primary endpoint: Adverse events (Subprotocols A-F)"},{"findings":[],"id":"T2","label":"Primary endpoint: Dose limiting toxicities (Subprotocols A-F)"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":5}],"id":"T3","label":"Primary endpoint: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1}],"id":"T4","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":1}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T6","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1}],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":3}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T03:40:57.571651Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T05:32:19Z","record_hash":"9080f3882b315ffadb862a6077e8f99b72f2f305e45913fdfcea7e3ba89703ba","release_hash":"082f8ab5a9514b682c6eee6b44f96ca6b045dcff9292d86bb3e4dccdfe7be3b1","report_id":"erudio-nct06445062","run_id":"11c737b4-3098-49c8-ab80-8664706c3d90","schema_version":"5.0","slug":"rmc-gi-102-06445062","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on RMC-GI-102 in the sources reviewed for this edition leads to one open question: Are response-prediction biomarkers being analyzed, which patient-selection criteria clarify who benefits, and what comparative benefit–toxicity evidence would justify changing first-line care? Its leading findings: (1) no added toxicity is not the same as a low treatment burden. (2) daraxonrasib enthusiasm is an early-signal interpretation, not demonstrated survival superiority. (3) zoldonrasib response enthusiasm carries explicit design and follow-up qualifications. 4 more findings follow. 31 sources screened, 19 cited; not all HCPs or all public discussion.","meta_description":"31 sources screened · 38 verified statements (13 from clinicians verified by NPI or staff page) from 19 sources · 7 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-29T05:32:19Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-29T05:45:46Z","summary":"Corrected to match the delivered report: the limitations. The trial's registration date is now stated."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":31},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not represent all HCPs or all public discussion. Unnamed references and different spellings may be missing.","One first-line daraxonrasib-monotherapy passage was not fully assessed, so additional views on that alternative may be absent.","Not every author's identity or clinical role is confirmed. Source-described credentials do not establish a verified clinical role, and channel ownership does not identify an anonymous speaker.","No protocol document or complete results publication is included. Detailed methods, endpoint ascertainment and mature comparative outcomes cannot be established from the commentary alone.","Regulatory coverage is incomplete, and exact labels for RMC-6236 and the mFOLFOX6 regimen are not included. Approval descriptions remain attributed to the announcements.","Most substantive discussion concerns PDAC. The platform's CRC cohorts and several registry-listed endpoints receive little or no specific commentary.","Not yet captured in this edition: a view on first-line RAS(ON) inhibitor monotherapy as an alternative treatment for metastatic pancreatic cancer.","Not yet captured in this edition: a view on first-line daraxonrasib monotherapy as an alternative treatment."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":17,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":19},"count":19,"evidence_window":{"end":"2026-09-18","start":"2024-12-18"},"retrieval_snapshot":"2026-10-29T03:18:37.274712Z","timeline":[{"count":1,"week":"2024-W51"},{"count":1,"week":"2025-W03"},{"count":3,"week":"2026-W16"},{"count":2,"week":"2026-W17"},{"count":2,"week":"2026-W26"},{"count":4,"week":"2026-W27"},{"count":2,"week":"2026-W28"},{"count":1,"week":"2026-W30"},{"count":3,"week":"2026-W38"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06445062:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06445062:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:40056080","quote_policy":"short_quote_link_out"},{"id":"openfda:4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe:20260821","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-rlwboxuuhaxwudp7iakmkoaw-3lntldd3j4k2z","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1800265962773426275:41c87be7-a2c0-4968-bbbf-1b5d7d51a686","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866248365941698723:f72f5ce4-1014-4583-aab3-cf744dfa4b6e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1869441388758384740:bdfca6b8-c2fb-460a-a892-8c515ec073dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1879545517774119105:38d0205a-3649-4c33-a582-5f54fb1920de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045270812689875449:a47b7906-9256-44bb-ba04-8f94b3471c55","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045292904768213086:01406de0-732f-4e81-9435-4cef74bf0ba9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045396104196317393:3c98acdf-71a1-469b-ad12-a6994c233ab5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045494993242988633:a3b2e847-b24e-4efb-9b3b-7339a240505f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2046486679867793635:de868eb3-0fbe-47a8-8fe3-f43dcb919815","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047072380581802462:d7a9120f-13d8-41d9-8f09-066c8f4744e0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069987997882163223:3a150392-3f53-48ff-9390-92f92d279340","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2071062768535621792:ddc63f55-0169-42e5-ae4d-73d7faf7fe95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072663911778734542:2399a46d-77c0-4380-bbda-0ca9018bd110","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072668121169572343:3c104196-7104-41f7-9950-b31bc16b725b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072671398678479138:e5c504da-947e-4973-bb28-31e6630d69e6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072684761554763823:d56245f9-8394-4f1c-b9af-ae4200230582","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072685313437106413:245acb13-4136-4ec7-ae4c-e0f4073610bb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2073495778799292464:56f89a70-e889-4348-82db-7be697f05237","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2073982918716993676:0d395f83-b75e-4ba7-81dc-f2712839935c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2073984065070612826:75ebc89a-7ab5-46de-b745-05468bf0e2b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074514869119050118:315b9e1e-8011-4b38-8c78-475016e97f62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099554434347147266:18c06df8-4b67-4fbc-9a3e-8655f33dc7c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099592248572932231:4e8faf71-f357-4d4b-b080-25ec30893e38","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099733470066901496:d0a38e52-1b98-4aaa-99ac-3337dafb5abc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099751869731983361:963aeb34-3524-47e8-a070-794c63975ec1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099810636595188071:9808add6-1318-4643-ab4e-af8298f2d397","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099821476404777124:69bd670c-d873-46fc-9e3c-4e40f1946260","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100544413986644122:1c79a778-6af6-49b3-84fb-333dcdb9d073","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ulCRcKu4F0s","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ws1EvEUE03Q","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":28,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":31},"count":31,"evidence_window":{"end":"2026-09-18","start":"2024-06-10"},"retrieval_snapshot":"2026-10-29T03:18:37.274712Z","timeline":[{"count":1,"week":"2024-W24"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2024-W51"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W18"},{"count":4,"week":"2026-W16"},{"count":2,"week":"2026-W17"},{"count":2,"week":"2026-W26"},{"count":7,"week":"2026-W27"},{"count":3,"week":"2026-W28"},{"count":1,"week":"2026-W30"},{"count":7,"week":"2026-W38"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: rmc-6236","status":"unmapped"},{"reason":"Unmapped registry intervention: mfolfox6 regimen","status":"unmapped"},{"brand_names":["Avastin"],"label":"bevacizumab","slug":"bevacizumab"},{"reason":"Unmapped registry intervention: mfolfirinox regimen","status":"unmapped"},{"brand_names":["Erbitux"],"label":"cetuximab","slug":"cetuximab"},{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"},{"brand_names":["Abraxane"],"label":"nab-paclitaxel","slug":"nab-paclitaxel"},{"reason":"Unmapped registry intervention: rmc-9805","status":"unmapped"},{"reason":"Unmapped registry intervention: folfiri regimen","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Colorectal cancer","slug":"colorectal-cancer"},{"reason":"Unmapped registry condition: CRC","status":"unmapped"},{"reason":"Unmapped registry condition: Pancreatic Ductal Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: PDAC","status":"unmapped"},{"reason":"Unmapped registry condition: Gastrointestinal Cancer","status":"unmapped"},{"reason":"Unmapped registry condition: Metastatic Pancreatic Ductal Adenocarcinoma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"RMC-GI-102","aliases":["RMC-GI-102","Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors"],"brief_title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Colorectal Cancer","CRC","Pancreatic Ductal Adenocarcinoma","PDAC","Gastrointestinal Cancer","Metastatic Pancreatic Ductal Adenocarcinoma"],"enrollment":{"count":1130,"type":"ESTIMATED"},"interventions":[{"name":"RMC-6236","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"mFOLFOX6 regimen","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"bevacizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"mFOLFIRINOX regimen","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"cetuximab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"gemcitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"nab-paclitaxel","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"RMC-9805","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"FOLFIRI regimen","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06445062","official_title":"A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","overall_status":"RECRUITING","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-09-30","type":"ESTIMATED"},"primary_endpoints":[{"description":"Evaluate the safety and tolerability in the study population characterized by incidence, abnormal laboratory assessments, severity, and seriousness of adverse events in relation to the study treatment.","measure":"Adverse events (Subprotocols A-F)","timeFrame":"Up to 3 years"},{"description":"Number of participants with dose limiting toxicities","measure":"Dose limiting toxicities (Subprotocols A-F)","timeFrame":"28 days"},{"measure":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)","timeFrame":"Up to 3 years"}],"registered_date":{"date":"2024-06-06","type":"ACTUAL"},"registry_last_updated":"2026-09-22","registry_url":"https://clinicaltrials.gov/study/NCT06445062","short_name":"RMC-GI-102","short_name_basis":"canonical_name","sponsor":"Revolution Medicines, Inc.","start_date":{"date":"2024-05-24","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase1, phase2","study_ids":[{"id":"RMC-GI-102","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}